肠道菌群与自身免疫性肝病的研究进展

doi:10.3969/j.issn.1004-583X.2021.06.020

摘要/Abstract

摘要：

自身免疫性肝病(autoimmune liver disease, AILD)是一组与自身免疫异常相关的疾病,主要包括自身免疫性肝炎(autoimmune hepatitis,AIH)、原发性胆汁性胆管炎(primary biliary cirrhosis, PBC)、原发性硬化性胆管炎(primary sclerosing cholangitis, PSC)等。肠道菌群是人体肠道复杂的生态系统,对人体生理功能产生着广泛影响。近年来,随着对肠道菌群研究的深入,以及对AILD认识的加深,肠道微生物谱与AILD关系的研究日益受到重视。多项研究发现,肠道菌群可能参与了AILD的发病及发展,对于肠道菌群失调的治疗可能成为AILD治疗的重要靶点。

中图分类号:

R575.1

赵小玲, 郑吉敏, 杜季康. 肠道菌群与自身免疫性肝病的研究进展[J]. 临床荟萃, 2021, 36(6): 574-576.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.06.020

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I6/574

参考文献 27

[1]	Dyson JK, Webb G, Hirschfield GM, et al. Unmet clinical need in autoimmune liver diseases[J]. J Hepatol, 2015, 62(1):208-218. doi: 10.1016/j.jhep.2014.09.010 URL
[2]	Ma HD, Wang YH, Chang C, et al. The intestinal microbiota and microenvironment in liver[J]. Autoimmun Rev, 2015, 14(3):183-191. doi: 10.1016/j.autrev.2014.10.013 URL
[3]	韩美林, 龚振华. 肠道菌群在肝胆疾病中的作用机制[J]. 临床肝胆病杂志, 2017, 33(2):384-388.
[4]	Peng H, Wisse E, Tian Z. Liver natural killer cells: Subsets and roles in liver immunity[J]. Cell Mol Immunol, 2016, 13(3):328-336. doi: 10.1038/cmi.2015.96 pmid: 26639736
[5]	Miyake Y, Yamamoto K. Role of gut microbiota in liver diseases[J]. Hepatol Res, 2013, 43(2):139-146. doi: 10.1111/hepr.2013.43.issue-2 URL
[6]	Wei Y, Zeng B, Chen J, et al. Enterogenous bacterial glycolipids are required for the generation of natural killer T cells mediated liver injury[J]. Sci Rep, 2016, 6:36365. doi: 10.1038/srep36365 URL
[7]	Fine RL, Manfredo Vieira S, Gilmore MS, et al. Mechanisms and consequences of gut commensal translocation in chronic diseases[J]. Gut Microbes, 2019, 11(2):1-14. doi: 10.1080/19490976.2019.1613124 URL
[8]	Lin R, Zhou L, Zhang J, et al. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J]. Int J Clin Exp Pathol, 2015, 8(5):5153-5160.
[9]	Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69(3):569-577. doi: 10.1136/gutjnl-2018-317836 URL
[10]	Liwinski T, Casar C, Ruehlemann MC, et al. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2020, 51(12):1417-1428. doi: 10.1111/apt.15754 URL
[11]	Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation[J]. Cell, 2014, 157(1):121-141. doi: 10.1016/j.cell.2014.03.011 URL
[12]	Liu Chen Kiow J, Vincent C, Sidani S, et al. High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis[J]. Neurogastroenterol Motil, 2019, 31(11):e13691.
[13]	Lv LX, Fang DQ, Shi D, et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis[J]. Environ Microbiol, 2016, 18(7):2272-2286. doi: 10.1111/1462-2920.13401 URL
[14]	Gao L, Wang L, Woo E, et al. Clinical management of primary biliary cholangitis-strategies and evolving trends[J]. Clin Rev Allergy Immunol, 2020, 59(2):175-194. doi: 10.1007/s12016-019-08772-7 URL
[15]	Li Y, Tang R, Leung P, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases[J]. Autoimmun Rev, 2017, 16(9):885-896. doi: 10.1016/j.autrev.2017.07.002 URL
[16]	黄春洋, 陈杰, 刘燕敏, 等. 肠道菌群在自身免疫性肝病发生发展及治疗中的作用[J]. 临床肝胆病杂志, 2019, 35(1):205-207.
[17]	Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3):534-541. doi: 10.1136/gutjnl-2016-313332 URL
[18]	Chung BK, Hirschfield GM. Immunogenetics in primary sclerosing cholangitis[J]. Curr Opinion Gastroenterol, 2017, 33(2):93-98. doi: 10.1097/MOG.0000000000000336 URL
[19]	Irlès-Depé M, Roullet S, Neau-Cransac M, et al. Impact of pre-existing inflammatory bowel disease on the outcome of liver transplantation for primary sclerosing cholangitis[J]. Liver Transpl, 2020, 26(11):1477-1491. doi: 10.1002/lt.v26.11 URL
[20]	Quraishi MN, Sergeant M, Kay G, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD[J]. Gut, 2017, 66(2):386-388.
[21]	Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J]. Gut, 2016, 65(10):1681-1689. doi: 10.1136/gutjnl-2015-311004 pmid: 27207975
[22]	Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls[J]. Gut, 2017, 66(4):611-619. doi: 10.1136/gutjnl-2015-310500 URL
[23]	Ruhlemann M, Liwinski T, Heinsen FA, et al. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis[J]. Aliment Pharmacol Ther, 2019, 50(5):580-589. doi: 10.1111/apt.15375 URL
[24]	Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis[J]. Nat Microbiol, 2019, 4(3):492-503. doi: 10.1038/s41564-018-0333-1 URL
[25]	Liao L, Schneider KM, Galvez E, et al. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis[J]. Gut, 2019, 68(8):1477-1492. doi: 10.1136/gutjnl-2018-316670 URL
[26]	Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis[J]. Gut, 2019, 69(4):2019-318416.
[27]	Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial[J]. Am J Gastroenterol, 2019, 114(7):1071-1079. doi: 10.14309/ajg.0000000000000115 pmid: 30730351

肠道菌群与自身免疫性肝病的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张晓璐, 李红山. 自身免疫性肝炎发病机制研究进展——聚焦“肠道菌群与免疫系统相互作用”[J]. 临床荟萃, 2024, 39(2): 177-182.
[2]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[3]	梅胜梅, 周俊英. 维生素D缺乏与自身免疫性肝炎相关性研究进展[J]. 临床荟萃, 2021, 36(9): 856-860.
[4]	王诗梦, 马英骥, 吴颖, 刘晓丹, 王伟. 乙型肝炎病毒感染对肿瘤肝转移影响的Meta分析[J]. 临床荟萃, 2021, 36(5): 389-394.
[5]	马光宇, 宋崇东, 韩语纯, 张荣福, 张哲, 程爽, 苏亚楠. 肠道菌群与阿尔茨海默病的研究进展[J]. 临床荟萃, 2021, 36(2): 174-178.
[6]	王园园, 程宁, 林海燕. 慢性乙型肝炎患者血清sST2与肝功能、血小板水平及Ishak评分的相关性[J]. 临床荟萃, 2021, 36(11): 976-980.
[7]	张立愔, 许龙, 吕冬云, 孙睿, 张国超, 盛雪. 肠道微生物菌群对阿尔兹海默症的相关作用机制[J]. 临床荟萃, 2021, 36(1): 84-88.
[8]	王晓玲，沈丽贤，李惠文，张亚芹，李瑶，吴书娜. 急性乙型肝炎患者pDCs上CD86表达变化及意义[J]. 临床荟萃, 2020, 35(8): 719-723.
[9]	原慧芳. 丙型肝炎病毒感染者胆囊疾病发生情况及临床分析[J]. 临床荟萃, 2020, 35(7): 620-623.
[10]	詹雅萍, 李娴, 朱香顺, 王国芬, 童筱君. 双歧杆菌四联活菌辅助治疗对高尿酸血症的临床分析[J]. 临床荟萃, 2020, 35(4): 344-347.
[11]	尹海庆1a，姚宝国2a，陈万贞1b，苏莉2b. 恶性肿瘤患者耐碳青霉烯肠杆菌感染危险因素及耐药性分析[J]. 临床荟萃, 2020, 35(2): 166-169.
[12]	朱萍1，路毓峰2a，王丽3，王红2b，杨莉2b，卢建华2b，李敏然2a，叶立红2b，陈秀丽2a. 肝脏组织炎症程度与血清HBeAg定量的相关性研究[J]. 临床荟萃, 2019, 34(7): 637-640.
[13]	高明，张松筠. 内分泌代谢罕见病的诊断和治疗[J]. 临床荟萃, 2019, 34(3): 219-224.
[14]	王彦坤1，马俊骥2，张明2. 细胞角蛋白7在肝硬化病理诊断中的作用[J]. 临床荟萃, 2019, 34(2): 124-127.
[15]	杜少严a，尹硕a，郝文洋b，王意浓b，孙晓彩c，李淑琴c. 硫化氢在肝脏疾病中的研究进展[J]. 临床荟萃, 2019, 34(12): 1127-1130.